Which is better in neoadjuvant treatment of breast cancer? Taxane followed by anthracyline or vice versa

By Altundag Kadri   Altundag Ozden   Baptista Mauricio   Atik Mustafa  

Breast Cancer Research and Treatment, Vol. 97, Iss. 2, 2006-05 ,pp. : 221-221

Springer Publishing Company

Access to resources Recommend Favorite

Neoadjuvant Chemotherapy for Breast Cancer: Does Pretreatment Axillary Nodal Staging Improve Decision Making?

By Batsis Charalabos  

Annals of Surgical Oncology, Vol. 16, Iss. 4, 2009-04 ,pp. : 1063-1064

Springer Publishing Company

Access to resources Recommend Favorite

Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages?

By Takei Hiroyuki  

Breast Cancer, Vol. 18, Iss. 2, 2011-04 ,pp. : 85-91

Springer Publishing Company

Access to resources Recommend Favorite

Selection of Primary Breast Cancer Patients for Adjuvant Endocrine Therapy – is Oestrogen Receptor Alone Adequate?

By Cheung K.L.  

Breast Cancer Research and Treatment, Vol. 65, Iss. 2, 2001-01 ,pp. : 155-162

Springer Publishing Company

Access to resources Recommend Favorite

Should bisphosphonates be utilized in the adjuvant setting for breast cancer?

By Lipton Allan  

Breast Cancer Research and Treatment, Vol. 122, Iss. 3, 2010-08 ,pp. : 627-636

Springer Publishing Company

Access to resources Recommend Favorite